Effects of Oral Levamisole as an Adjuvant to Hepatitis B Vaccine for protective antibody production in HIV/AIDS Patients: A Randomized Controlled Trial

Phase 4

• Conditions: HIV/AIDS.; HIV disease resulting in other viral infections; B20.3 Huma

• Registration Number: IRCT201207275349N2
• Lead Sponsor: Kermanshah University of Medical Science

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

HIV infection confirmed by positive double ELISA and WB ;Negative history for HBV infection or vaccination include: Negative tests for HBS-Ag, HBS-Ab abd HBC-Ab; Signature of Informed consent form by participant
Exclusion criteria: Refuse the study by participant

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Protective HBS-Ab level which is above 10 IU/ml. Timepoint: with the second and the third times of vaccination and one and three months after that, as well. Method of measurement: HBS-Ab measurement by ELISA method.

Secondary Outcome Measures

Name	Time	Method
HBS-Ab titre by IU/ml. Timepoint: with the second and the third times of vaccination and one and three months after that, as well. Method of measurement: tittering of HBS-Ab by ELISA method according to IU/ml.